Pooled efficacy outcomes with stroke prevention strategies directly compared with warfarin
| Warfarin (events/n) | Comparator (events/n) | Pairwise meta-analysis, odds ratio (95% CI) | Heterogeneity, I2, p value | |
|---|---|---|---|---|
| All-cause mortality | ||||
| Warfarin vs NOAC | 2250/29 909 | 3212/43 048 | 0.89 (0.84 to 0.94) | 0.0%, p=0.881 |
| Warfarin vs LAAC | 47/382 | 64/732 | 0.68 (0.45 to 1.02) | 0.0%, p=0.387 |
| Warfarin vs APT | 254/2685 | 335/2865 | 1.17 (0.97 to 1.40) | 25.8%, p=0.223 |
| Warfarin vs placebo | 50/770 | 124/925 | 1.75 (1.21 to 2.52) | 51.8%, p=0.126 |
| Stroke or systemic embolism | ||||
| Warfarin vs NOAC | 1129/29 936 | 1488/43 262 | 0.88 (0.81 to 0.95) | 45.7%, p=0.101 |
| Warfarin vs LAAC | 21/382 | 36/732 | 0.84 (0.48 to 1.49) | 50.6%, p=0.155 |
| Warfarin vs APT | 150/4933 | 321/5073 | 1.95 (1.59 to 2.40) | 47.4%, p=0.065 |
| Warfarin vs placebo | 32/770 | 138/925 | 3.54 (2.36 to 5.31) | 0.0%, p=0.883 |
APT, antiplatelet therapy; LAAC, left atrial appendage closure; NOAC, non-vitamin K antagonist oral anticoagulants.